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Abstract
Background and purpose: The aim was to conduct a pilot
study of selected epidemiological aspects of multiple sclero-
sis (MS) in Poland. 
Material and methods: Cross-sectional data were collected
in 21 centres providing MS treatment. The demographic pro-
file of the patients, medical history of MS, disability status,
comorbidity, and diagnostic and treatment modalities were
analysed. 
Results: Data on 3581 patients were obtained, including 2494
women (69.6%) and 1030 men (28.8%) – sex ratio 2.4 : 1.
The mean age was 40.7 ± 11.9 years. Monofocal onset was
reported in 80.8% of cases – the most frequently reported
location of lesions was supratentorial (36.1%), followed by
optic nerves (26.5%) and spinal cord (20.1%). The mean
disease duration was 10.2 ± 8.8 years (range 0.04-53 years),
and the mean time from the first symptoms to MS diagnosis
was 2.6 years. Relapsing-remitting MS was reported in 70.5%
of patients, secondary progressive in 16.8%, primary pro-
gressive in 8.4%, and ‘benign MS’ in 2.5%. The mean
EDSS score was 3.3 ± 2.2 (range 0-9.5). The family histo-
ry of MS was positive in 6.4% of cases. Comorbidity mainly
applied to the musculoskeletal system (6.5%), the urinary sys-
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St reszc zen ie
Wstêp i cel pracy: Celem badania by³a pilota¿owa analiza
wybranych aspektów epidemiologicznych stwardnienia roz-
sianego (SR) w Polsce. 
Materia³ i metody: Przekrojowe dane zebrano w 21 oœrod-
kach prowadz¹cych leczenie SR. Analizowano profil demo-
graficzny chorych, wywiad chorobowy SR, stopieñ niepe³no -
sprawnoœci, choroby wspó³wystêpuj¹ce, metody diagnostyczne
i stosowane leczenie. 
Wyniki: Uzyskano dane 3581 pacjentów, w tym 2494 kobiet
(69,6%) i 1030 mê¿czyzn (28,8%) – proporcja p³ci 2,4 : 1.
Œredni wiek wynosi³ 40,7 ± 11,9 roku. Pocz¹tek jednoognis-
kowy odnotowano w 80,8% przypadków – najczêœciej wska-
zywano na nadnamiotow¹ lokalizacjê uszkodzeñ (36,1%),
w dalszej kolejnoœci zajête by³y nerwy wzrokowe (26,5%)
i rdzeñ krêgowy (20,1%). Choroba trwa³a œrednio 10,2 ± 8,8
roku (zakres 0,04–53 lat), a od pierwszych objawów do usta-
lenia rozpoznania mija³o œrednio 2,6 roku. Postaæ nawra-
caj¹co-zwalniaj¹c¹ SR mia³o 70,5% chorych, wtórnie
postêpuj¹c¹ – 16,8%, pierwotnie postêpuj¹c¹ – 8,4%, u 2,5%
rozpoznano zaœ „³agodne” SR. Œredni stopieñ niesprawnoœci
w skali EDSS wyniós³ 3,3 ±2,2 (zakres 0–9,5). Rodzinne
wystêpowanie SR odnotowano w 6,4% przypadków. Wœród
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Introduction
Multiple sclerosis (MS), a chronic demyelinating
disease, is a leading cause of neurological disability in
young adults. The course of the disease and the rate of
disability progression are highly unpredictable. It is esti-
mated that roughly 1 million people worldwide suffer
from MS [1], although the exact number is not known. 
In Poland no epidemiological study covering a repre-
sentative group of MS patients throughout the entire
country has been conducted so far. In fact only a few 
epidemiological surveys have been carried out, and 
all of these have been limited to particular regions of
Poland [2-5]. 
The purpose of this study was to collect data on the
demographic profile, health status and diagnostic and
therapeutic modalities of MS patients in Poland. 
Material and methods
The process of cross-sectional data collection start-
ed in May 2008 and was completed in January 2009.
The project involved 21 centres (university clinics, hos-
pital wards, outpatient clinics and private surgeries) from
almost the entire territory of Poland except for the fol-
lowing provinces: pomorskie, kujawsko-pomorskie, ³ódzkie
and podkarpackie. 
The data were collected using a specially designed
form (paper questionnaire and an alternative electronic
form), which included queries about: demographic data,
family history, concomitant diseases, first MS symptoms,
disease duration, relapse activity, degree of disability on
the Expanded Disability Status Scale (EDSS) [6], diag-
nostic methods, and immunomodulatory/immunosup-
pressive therapy. In addition, the study assessed the
patients’ quality of life using the EQ-5D scale (results
of the quality of life assessment will be published sepa-
rately). Doctors participating in the study were asked 
to take into account the data of all patients under their
care in whom MS had been diagnosed based on the
McDonald criteria [7,8], regardless of age, disease form
or disability status. 
The collected data were analysed using Statistica 7.1
(StatSoft, US) and GraphPad Prism 5.0 (GraphPad
Software, US).
A quality check of the data included cross-compa -
rison of parameters gathered in the project. In case of
inconsistency (e.g., the date of first symptoms was later
than the date of MS diagnosis), the inconsistent data
were not taken into account in the analysis.
For the collected data, descriptive statistics of their dis-
tribution were calculated, with mean/median values, quar-
tiles, standard deviations and 95% confidence intervals.
Results
In our project, data from 3851 patients were collected,
including 2494 women (69.6%) and 1030 men (28.8%).
The female/male ratio in the study group was 2.4 : 1.
tem (5.8%) and psychiatric disturbances (5.5%). Brain
magnetic resonance studies were available in 96.3% of the
patients, evoked potentials in 54%, and cerebrospinal fluid
testing in 63.1% – of whom only 41.2% were tested for oli-
goclonal bands, with 84% of samples being positive. Immu-
nomodulatory drugs were used in 842 patients (24%), pre-
dominantly interferon beta (81%) and glatiramer (13%).
Mitoxantrone was the most commonly used immunosup-
pressant.
Conclusions: This project is the first countrywide large-scale
MS survey, covering approximately 18% of patients, accor-
ding to our estimates. The results identify the clinical condi-
tion of the patients, as well as diagnostic and treatment moda-
lities.
Key words: multiple sclerosis, Poland, epidemiology, dia-
gnostics, treatment.
chorób wspó³wystêpuj¹cych najczêstsze by³y schorzenia
narz¹du ruchu (6,5%), uk³adu moczowego (5,8%) i zabu-
rzenia psychiczne (5,5%). Rezonans magnetyczny mózgu
wykonano u 96,3% pacjentów, potencja³y wywo³ane u 54%,
badanie p³ynu mózgowo-rdzeniowego u 63,1% – z czego
zaledwie w 41,2% przypadków oznaczano pr¹¿ki oligoklo-
nalne (ich obecnoœæ stwierdzono w 84% próbek). Leki immu-
nomoduluj¹ce otrzymywa³o 842 chorych (24%), najczêœciej
by³y to interferon β (81%) i glatiramer (13%). W immuno-
supresji najczêœciej stosowano mitoksantron.
Wnioski: Zrealizowany projekt jest pierwszym ogólnopol-
skim badaniem populacji chorych na SR na tak szerok¹ ska-
lê – wg naszych szacunków obejmuj¹cym ok. 18% populacji
chorych. Zgromadzone wyniki informuj¹ o stanie klinicznym
chorych, najczêstszych metodach diagnostyki i leczenia.
S³owa kluczowe: stwardnienie rozsiane, Polska, epidemiolo-
gia, diagnostyka, leczenie.
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The patients originated from 21 study sites, includ-
ing academic centres (60.9% of patients), non-academ-
ic specialty centres (31.4%), private practice (6.3%) and
municipal healthcare units (1.4%). The patient’s setting
(whether in- or outpatient) was not recorded.
Geographical location of the study sites is presented
in Table 1.
The mean age of the analysed cohort was 40.7
± 11.9 years (range 11.2-92.3), while the mean age of
women was 40.7 ± 11.8 years (range 11.2-92.3) and of
men was 40.6 ± 12.1 years (range 11.8-88.2). 
The mean age at disease onset was 30.4 ± 9.8 years, and
the mean duration of the disease in the study group was
10.2 ± 8.8 years. An average of 2.6 ± 4.3 years elapsed
from the onset of first symptoms to MS diagnosis.
Detailed patient characteristics including relapse activ-
ity are presented in Table 2.
Site location No. of Patients 
(region) study sites n (%)
dolnoœl¹skie 1 200 (5.6%)
lubelskie 3 1016 (28.4%)
lubuskie 1 90 (2.5%)
ma³opolskie 1 107 (3%)
mazowieckie 1 57 (1.6%)
opolskie 1 60 (1.7%)
podlaskie 1 199 (5.6%)
œl¹skie 2 297 (8.3%)
œwiêtokrzyskie 2 165 (4.6%)
warmiñsko-mazurskie 1 134 (3.7%)
wielkopolskie 4 703 (19.6%)
zachodniopomorskie 3 553 (15.4%)
Table 1. Geographical distribution of the study sites and the patient cohort
Females Males All patients*
No. of patients 2494 1030 3581
Proportion: female/male – – 2.4 : 1
Age  
mean (SD) 40.7 (11.8) 40.6 (12.1) 40.7 (11.9)
median (range) 40.5 (11.2-92.3) 39.4 (11.8-88.2) 40.1 (11.2-92.3)
Disease duration [years]
mean (SD) 10.2 (8.7) 10.4 (9.1) 10.2 (8.8)
median (range) 7.8 (0.08-53.1) 7.5 (0.04-50.8) 7.6 (0.04-53.1)
Age at disease onset [years]
mean (SD) 30.6 (10.1) 30.2 (9.0) 30.4 (9.8)
median (range) 29.5 (5.08-66.4) 29.0 (4.76-58.5) 29.3 (4.8-66.4)
Total number of prior relapses        
mean (SD) 5.73 (4.29) 5.38 (4.39) 5.62 (4.31)
median (range) 4 (0-28) 4 (0-35) 4 (0-35)
Number of relapses in the last year (by category)
≤ 1 relapse 1721 (69.0%) 735 (71.4%) 2496 (69.7%)
2 relapses 213 (8.5%) 98 (9.5%) 315 (8.8%)
3 relapses 39 (1.6%) 13 (1.3%) 52 (1.5%)
≥ 4 relapses 11 (0.4%) 2 (0.2%) 13 (0.4%)
unknown 510 (20.4%) 182 (17.7%) 705 (19.7%)
Table 2. Patient characteristics
*Gender was not specified in 57 cases
SD – standard deviation
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The disease onset in the majority of patients was
monofocal (2896/3581, 80.8%). The most common
locations of the first symptoms are presented in Fig. 1. 
Multifocal onset occurred in 561/3581 patients
(15.7%), as follows: two symptoms in 506 patients (14.1%),
three symptoms in 52 patients (1.5%), four symptoms in
3 patients (0.08%). No data on the location of the first
symptoms were available from 124 patients (3.5%). 
A majority of the study group (2523/3581, 70.5%)
had relapsing-remitting multiple sclerosis (RRMS).
Detailed data on the occurrence of specific forms of the
disease are shown in Fig. 2. 
In this study ‘benign MS’ has been singled out; it is
defined as the occurrence of relapses with complete
remission, or very minor impairment and disability not
exceeding an EDSS score of 3 after 10 years from 
the disease onset. This form of MS was presented by
only 2.5% of the patients. 
The degree of disability as evaluated by the EDSS
score was 3.34 ± 2.20 (range 0-9.5) – see Table 3.
The histogram of the percentage distribution of the vari-
able and the categorised distribution by intervals are pre-
sented in Fig. 3 and Table 3, respectively.
Patients with mobility restricted to an extent that at
least required the use of a cane (EDSS ≥ 6) accounted for
19.7% of the study group. Patients who were unable to
walk without aid and required a wheelchair constituted
5% of the sample. The analysis showed a statistically sig-
nificant correlation between disease duration and degree
of disability, both in patients with relapsing-remitting
(r2=0.3095, p< 0.0001) and in those with primary pro-
gressive (r2= 0.1737, p< 0.0001) MS – see Fig. 4.
Family history data for MS were recorded in 2871
patients, of whom a negative history was found in 2687
(93.6%), and a positive history in 184 patients (6.4%).
No history information was available in 710 (19.8%)
patients. Out of the 184 cases in which the family his-
tory was positive, 7 patients had more than one family
member with the disease; for details see Table 4.
The study also collected data on the occurrence of
other disease burdens besides MS. Disease burdens
were grouped according to the MedDRA SOC inter-
national classification. The absence of any burdens 
(other than the underlying disease) was reported in 2405
(67.2%) patients. The remaining patients (32.8%) had
a history indicative of dysfunction primarily in the fol-
lowing organ systems: musculoskeletal system, urinary
system, mental disorders and other central nervous sys-
tem disorders. These dysfunctions occurred with an inci-
dence of > 5% in the study group. Detailed data on
comorbidity in the study group are shown in Fig. 5.
The frequency of use of the following examinations
was also assessed: magnetic resonance imaging (MRI)
of the brain, evoked potentials and cerebrospinal fluid
testing, including determination of the presence of oligo-
clonal bands (Fig. 6). 
In the study group, diagnosis of MS was made
exclusively on the basis of the clinical picture in only
11 patients (0.3%).
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First symptoms No. of pts. %
supratentorial 1046 36.1
optic nerves 766 26.5
spinal cord 581 20.1
brain stem 242 8.4
cerebellum 223 7.7
other 38 1.3
monofocal
multifocal
no data
3.5%
80.8%
15.7%
SPMS – secondary progressive multiple sclerosis, RRMS – relapsing-remitting multiple scle-
rosis, PPMS – primary progressive multiple sclerosis
Fig. 2. Multiple sclerosis types in the study group – percentage distribution
RRMS
SPMS
PPMS
Benign MS
No data
16.8%
70.5%
8.4%
2.5%
1.8%
Fig. 1. First symptoms location – percentage distribution
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Females Males All patients*
No. of available scores 2494 1030 3581
EDSS score  
mean (SD) 3.31 (2.16) 3.47 (2.28) 3.34 (2.20)
median (range) 3 (0-9.5) 3 (0-9.5) 3 (0-9.5)
EDSS score by category
≤ 1.5 696 (27.9%) 294 (28.5%) 1012 (28.3%)
2.0-2.5 484 (19.4%) 158 (15.3%) 648 (18.1%)
3.0-3.5 355 (14.2%) 144 (14.0%) 506 (14.1%)
≥ 4.0 904 (36.2%) 410 (39.8%) 1331 (37.2%)
unknown 55 (2.2%) 24 (2.3%) 84 (2.3%)
Table 3. Disability assessment (EDSS score) in the studied cohort
*gender was not specified in 57 cases
EDSS – Expanded Disability Status Scale; SD – standard deviation
Involved family member n %
Member of extended family 85 50.0
Sister 28 16.5
Mother 19 11.2
Father 17 10.0
Brother 14 8.2
Mother + member of extended family 2 1.2
Father + member of extended family 2 1.2
Sister + member of extended family 1 0.6
Brother + member of extended family 1 0.6
Brother + mother 1 0.6
Table 4. Details of familial occurrence of MS – percentage distribution of involved
family members
Fig. 3. Disability score (EDSS) in the studied cohort – percentage distribution
Dashed lines demarcate 95% CI of the linear regression line
Fig. 4. Correlation between disease duration and EDSS score in primary progressive (PPMS) and relapsing-remitting multiple sclerosis (RRMS)
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MRI was performed in 3446 patients (96.2%).
Information regarding the use of contrast enhancement
was achieved for 2509 patients. Out of this group, imag-
ing was carried out using contrast enhancement in
73.7% (1850 patients). Lesions in T2-weighted images
typical of MS were found in 3208 cases (89.6%), in
43 cases (1.2%) changes were atypical for MS, while in
19 patients (0.5%) images were normal. No data were
available for 311 patients (8.7%). In the event of focal
lesions, radiological descriptions did not state their exact
number in 85.4% of cases (2943 patients).
Testing of the cerebrospinal fluid was documented
in 2258 patients (63.1%). Out of this group, the test for
the presence of oligoclonal bands was performed in only
930 (41.2%) patients. In patients who had their cere-
brospinal fluid tested for oligoclonal bands, these were
found in 785/930 (84%) patients.
Evoked potentials were recorded in 1933 patients
(54%); this test was not performed in 1645 patients
(45.9%) and in 3 cases (0.08%) no information was pro-
vided on whether such a test had been performed.
The questionnaires also reported whether the
patients were treated with immunomodulating or
immunosuppressive drugs (with the exception of
steroids).
The number of patients receiving immunomodula-
tory drugs at the time of the study was 842 (24%), while
94 patients (3%) were receiving immunosuppressive
drugs. Mitoxantrone (81%) and azathioprine (18%)
were among the most widely used immunosuppressive
agents.
The percentage distribution of different immuno -
modulatory drugs is presented in Fig. 7 (immunoglo -
bulin G is omitted because it was taken by one patient
only). The category of ‘experimental drugs’ includes all
pharmaceutical products taken within a clinical trial set-
ting, including double-blinded placebo-controlled stud-
ies.
Table 5 shows a summary of all immunomodulato-
ry and immunosuppressive agents that have ever been
taken by the patients (n = 1836) in the study group. 
It should be noted that the chart takes into account the
fact that a patient could take more than one drug.
Discussion
During the study, data on 3851 patients were col-
lected. Given the prevalence of multiple sclerosis of
55-57/100 000 found in the epidemiological studies con-
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EP – evoked potentials, MRI – magnetic resonance imaging, CSF – cerebrospinal fluid
Note: individual diagnostic tests might not necessarily be performed at the time of primary
diagnosis of MS
Fig. 6. Percentage of patients in whom the below diagnostic tests were used
vs. the year of diagnosis
19
60
-19
65
19
65
-19
70
19
70
-19
75
19
75
-19
80
19
80
-19
85
19
85
-19
90
19
90
-19
95
19
95
-20
00
20
00
-20
05
20
05
+
100
90
80
70
60
50
40
30
20
10
0
PPaa
ttiiee
nnttss
  [[%%
]]
EP
MRI
CSF
Fig. 7. Patients under immunomodulatory treatment (excluding steroids) –
percentage distribution
none immunomodulators no data
72%
n = 2485 46%
6%
18%
17%
13%
24%
n = 842
interferon 
beta-1b
interferon 
beta-1a i.m.
interferon 
beta-1a s.c.
experimental
medication
glatiramer
4%
n = 147
Fig. 5. Comorbidity in the study group
Mu
scu
los
kel
eta
l
Ren
al/
uri
nar
y
Psy
chi
atr
ic
Ne
rvo
us 
sys
tem
Vas
cul
ar
Inf
ect
ion
s
Car
dia
c
End
ocr
ine
Ga
stro
inte
stin
al Eye
He
pat
obi
liar
y
Rep
rod
uct
ive
Res
pir
ato
ry
Ski
n/s
ubc
uta
neo
us
Me
tab
olis
m/
nut
riti
on
Blo
od/
lym
pha
tic
Ear
/la
byr
inth
Im
mu
ne
Ne
opl
asm
s
Con
gen
ital
/fa
mil
ial
7
6
5
4
3
2
1
0
PPaa
ttiiee
nnttss
  [[%%
]]
Year of diagnosis
Neurologia i Neurochirurgia Polska 2010; 44, 5 449
Epidemiology of multiple sclerosis in Poland
ducted in the north-western [4] and in the eastern parts
of Poland [5], it seems that the examined group repre-
sents roughly 18% of the entire population of Polish MS
patients.
In the study group, a significant female predomi-
nance was evident (female to male ratio of 2.4 : 1) that
was comparable to previously reported observations
[9-13]. Some recent publications show that the female
predominance in MS patients seems to be gradually
increasing [14]. Also other demographic data, i.e., age
at disease onset and disease duration, do not differ sig-
nificantly from those ascertained in the course of epi-
demiological studies conducted in various regions of
Poland [4,5], as well as in a neighbouring country –
Germany [11].
In most patients, the disease onset was monofocal,
with symptoms indicative mainly of supratentorial loca-
tion of lesions. The data are consistent with the reports
of other authors who observed a monofocal onset of MS
in more than 80% of patients [15]. 
Compared to other observations [5,11,16], we found
a shorter time lag between the occurrence of the first
symptoms and diagnosis, which in our study was 2.6 years
on average. It seems that the introduction of the McDo -
nald diagnostic criteria and better access to MRI con-
tribute to the improvement of the diagnosis [17].
In the study group, most patients reported a relaps-
ing-remitting form of the disease (70.5%), with relapse
activity within the last 12 months ranging from 0 to 6
relapses – a mean of 0.7 relapses per patient. A relatively
small fraction of patients had the secondary progressive
(16.8%), primary progressive (8.4%) and benign (2.5%)
course of the disease. Compared to data from the lite -
rature on the natural course of MS [9,18], we noted in
our group an over-representation of the relapsing-remit-
ting form of MS and consequently under-representa-
tion of other forms. This is probably due to the fact that
the study primarily included centres involved in
immunomodulatory therapy and it is this group of
patients (who return regularly for medication) that neu-
rologists have the easiest access to. 
The patients’ degree of disability was assessed on the
EDSS scale. The mean score was 3.3. Having taken into
account the mean duration of the disease (10.2 years),
the mean degree of disability that we recorded is very
close to the German observation, which is similar in
terms of methodology (mean EDSS = 3.5, mean dis-
ease duration 12.7 years) [11]. In the subgroup with
higher levels of disability (EDSS ≥ 4) a larger propor-
tion of men (39.8%) compared to women (36.2%) was
found, which is in agreement with previous reports indi-
cating more severe disease course in males [19].
Data collected on concomitant diseases indicate that
most patients (67.2%) did not have any burdens beyond
the underlying disease. Most frequently (in more than
5% of patients) reported concomitant diseases belonged
to the following three categories: 1) muscular and con-
nective tissue, bones; 2) kidneys and the urinary system;
3) mental disorders. Because in the questionnaire, neu-
rologists only reported the categories of concomitant dis-
eases (without specifying the diagnosis), from a practi-
cal point of view it is difficult to resist the impression
that the problems mentioned may be causally related to
the underlying disease, e.g., the presence of paresis and
spasticity predisposes to spinal pain syndrome, micturi-
tion disturbances are associated with urinary tract infec-
tions, and disorders of mood and cognitive functions are
very common in patients with MS. However, cancer or
cardiovascular diseases frequently occurring in the gen-
eral population were very rarely recorded in the study
group of patients.
Data on the prevalence of MS in the patient’s fam-
ily were available for 2871 patients – in 184 cases dis-
ease in their relatives was reported. Out of these indi-
viduals, 5 patients reported more than one case of MS
in the family (excluding the proband). In such cases
a first-degree relative was always one of the affected fam-
ily members and siblings were most often involved
rather than parents. Our data are similar to other pre-
Immunomodulator No. of patients % of cases
/immunosuppressant
Interferon beta-1b 728 43.2
Interferon beta-1a (S.C.) 251 14.9
Interferon beta-1a (I.M.) 206 12.2
Glatiramer acetate 199 11.8
Investigational drug 180 10.7
Mitoxantrone 170 10.1
Azathioprine 74 4.4
Immunoglobulin G 19 1.1
Cyclophosphamide 9 0.5
TOTAL 1836 109.0*
Table 5. Immunomodulatory/immunosuppressive agents that have ever been
taken in the studied cohort (steroids not included)
S.C. – subcutaneous, I.M. – intramuscular
*Percentages of cases do not add up to 100 because some patients were administered more
than one drug
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vious observations in terms of the family pattern of the
disease occurrence [15,20].
Data collected on diagnostic methods show that
MRI (not always contrast-enhanced) is currently the
most widely used supporting test in the diagnosis of MS,
and its use has significantly increased in recent years.
MRI was performed in 96.2% of patients. Unfortu-
nately, we found that in 85.4% of the cases radiological
descriptions did not specify the exact number of lesions.
The lack of precise MRI descriptions undoubtedly ren-
ders radiological diagnostic criteria difficult to imple-
ment in routine practice [21,22].
Cerebrospinal fluid was examined in 63.1% of
patients. The use of this test has decreased in recent
years, which may be due to easier access to non-invasive
diagnostic methods. In patients who had their cere-
brospinal fluid tested, the presence of oligoclonal bands,
which are indicative of intrathecal synthesis of
immunoglobulins [23,24], was assessed in only 41.2%
of the patients. In approximately 8% of patients there
was no information in this regard. This information sug-
gests that intrathecal synthesis of immunoglobulins,
which should be evaluated in each patient with suspect-
ed MS in whom cerebrospinal fluid is collected for test-
ing, is evaluated too infrequently. The relatively low fre-
quency of oligoclonal band testing is probably due to
methodological difficulties, deficiency of proper equip-
ment and lack of experienced diagnosticians.
In more than half of the patients, tests of evoked
potentials were performed, yet our survey did not spec-
ify their type. In the context of widespread use of MRI,
the large inter-subject variability of evoked potentials
[25,26], and the introduction of the McDonald diag-
nostic criteria, which take into account visual evoked
potentials only in the diagnosis of primary progressive
MS [7], it may be somewhat surprising that the fre-
quency of electrophysiological tests has not decreased.
Perhaps this is due to their non-invasive nature, wide
availability and relatively low cost.
At the time of data collection, immunomodulatory
drugs were being given to 842 respondents (24%) –
these were mainly beta-interferons (81%), but 6% of the
patients also participated in clinical trials of various
drugs. The observed treatment rate (24%) is consider-
ably higher than the estimates provided by the patient
advocacy groups (about 5%). This may stem from the
fact that the study mainly involved centres engaged in
immunomodulatory treatment, and it does not change
the fact that immunomodulatory drugs are used in
Poland much less frequently than in Western European
countries, e.g., in Germany about 50% of patients
receive such treatment [11]. Immunosuppressive agents
were used in 94 patients (3%), which is in turn much
less than, for example, in Germany (approximately 16%)
[11]. Like in Poland’s western neighbours, mitox-
antrone and azathioprine were the most frequently
administered drugs. The study did not examine the use
of steroids.
This was a cross-sectional study, and it primarily
involved centres engaged in immunomodulatory thera-
py. Judgement regarding the level of access to
immunomodulatory treatment in particular regions of
the country is difficult, since not all of the MS centres
which provide immunomodulatory treatment partici-
pated in this study.
Data that may shed some light on this matter can
however be obtained from independent research com-
panies monitoring the pharmaceutical market in Poland
(e.g. IMS Health Poland). These reports show that the
number of MS patients receiving disease-modifying
treatment varies widely between regions, with the high-
est numbers of treated patients in wielkopolskie and
ma³opolskie regions and the lowest in lubuskie, warmiñsko-
mazurskie and opolskie (IMS Health data Q3/2009; used
with permission of IMS Health Poland).
Estimates regarding the percentage of MS patients
with immunomodulatory therapy remain dubious, as the
exact prevalence of the disease in Poland is unknown.
If, however, absolute numbers of treated patients are
compared to the population of the regions, still wielkopol-
skie and ma³opolskie provinces have the highest propor-
tions of treated patients, while œl¹skie and warmiñsko-
 mazurskie have the lowest – although the former region
has a relatively high absolute number of treated patients
(more than 200). There is more than a threefold differ-
ence between the region with the highest and the one
with the lowest proportion of treated patients.
The large variation of the study centres should be
noted – the study looked at patients treated in universi-
ty clinics, hospital wards, outpatient clinics and private
surgeries, located both in large urban areas and in small
towns. The obtained database thus allows us to assess
diverse patient populations. Although in some cases the
precision of data collection (lack of responses to certain
questions) has raised concerns, this project is the first
epidemiological study of multiple sclerosis in Poland car-
ried out on such a large scale, providing an insight into
the health situation of the Polish population of patients.
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Conclusions
1. We estimate that this first countrywide survey in MS
patients covered approximately 18% of the Polish pop-
ulation of these patients.
2. The demographic characteristics of patients studied are
similar to those obtained during population-based epi-
demiological studies conducted in several Polish regions,
which seems to indicate that the data collected are rep-
resentative of the Polish population of MS patients.
3. Only the fact that the study primarily involved cen-
tres engaged in immunomodulatory therapy may
slightly distort some of the results, e.g., by overesti-
mating the proportion of patients treated with disease-
modifying drugs.
4. Like in other countries, it is strongly advisable to
establish a nation-wide MS registry that would allow
the precise determination of the prevalence and inci-
dence of multiple sclerosis in Poland, as well as to help
determine the necessity for healthcare.
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